Amgen continues to seek places to invest to increase its revenues as its older anemia drugs and Enbrel lose steam in the market. To this end, it has been named prominently by analysts as one of the companies likely to bid for Actelion and its blockbuster drug Tracleer.
Now reports are surfacing (Fierce Biotech) that Amgen CEO Kevin Sharer met with Actelion CEO Jean-Paul Clozel to feel him out on a potential deal. Word is that Clozel would prefer not to sell, but would not turn down the discussion with a big suitor like Amgen. Bayer and Eli Lilly are also rumored to be circling so Clozel may have a couple of other meetings in his future -- a future that could bring up to a $10 B offer for Actelion.
Posted by Bruce Lehr December 13th 2010.